Amgen
Search results
At Regeneron, we've been committed to making a difference in patients' lives for over 30 years. We've done this by following the science. One of the things that's made Regeneron really unique is its willingness to invest in cutting edge technologies.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron is a leading biotechnology company using the power of science to bring new medicines to patients in need. Explore Regeneron's global presence.
Discover how Regeneron helps people with serious diseases by exploring our FDA-approved medicines, industrial operations, investigational pipeline and more.
At Regeneron, we move science to medicine because our world is meant for more. Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.
Regeneron's goal is to address serious medical conditions, across multiple and diverse therapeutic areas. View our portfolio of FDA-approved medicines here. Our antibody combination is not currently authorized for use in any U.S. region.
4 days ago · We are a leading science and technology company that delivers life-transforming medicines for serious diseases. Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in many FDA-approved medicines and numerous product candidates in a range of diseases, including blindness-causing eye diseases, severe ...
Monitor SARS-CoV-2 variants with Regeneron’s COVID-19 Dashboard. Refreshed daily with new genomes and associated patient metadata. Learn how Regeneron is actively working on testing existing medicines and developing new antibodies to combat the COVID-19 pandemic.
Jul 30, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorization (EUA) for the investigational COVID-19 antibody cocktail REGEN-COV™ (casirivimab and imdevimab). The authorization now includes post-exposure prophylaxis in people at high risk for progression ...
Mar 23, 2021 · Regeneron will share new data with regulatory authorities immediately and request that a lower 1,200 mg dose be added to EUA. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalized patients (n=4,567). This definitive Phase ...
